Vulcan Value Partners LLC Trims Stock Position in Medpace Holdings, Inc. $MEDP

Vulcan Value Partners LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 141,743 shares of the company’s stock after selling 61,325 shares during the period. Medpace comprises approximately 2.3% of Vulcan Value Partners LLC’s holdings, making the stock its 12th biggest position. Vulcan Value Partners LLC’s holdings in Medpace were worth $75,066,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Johnson Financial Group Inc. bought a new stake in Medpace during the second quarter valued at approximately $27,000. Elyxium Wealth LLC bought a new position in Medpace in the fourth quarter worth approximately $30,000. Jones Financial Companies Lllp purchased a new position in shares of Medpace during the 2nd quarter worth $30,000. Allied Private Wealth LLC purchased a new position in shares of Medpace during the 2nd quarter worth $31,000. Finally, Kilter Group LLC bought a new stake in shares of Medpace during the 2nd quarter valued at $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares of the company’s stock, valued at $2,302,157.70. This represents a 65.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian T. Carley sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 134,471 shares of company stock worth $82,151,311. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Down 0.1%

MEDP stock traded down $0.40 during mid-day trading on Tuesday, hitting $590.89. The company had a trading volume of 185,216 shares, compared to its average volume of 338,222. The company has a 50-day moving average price of $575.80 and a 200 day moving average price of $501.17. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The company has a market capitalization of $16.49 billion, a price-to-earnings ratio of 34.64, a P/E/G ratio of 2.64 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Royal Bank Of Canada upped their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. TD Cowen boosted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Mizuho raised their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $595.20.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.